We are live on ! Find out more
FOLD

Amicus Therapeutics
FOLD

Delisted

FOLD was delisted on the 24th of April, 2026.

Back to rankings

2 hedge funds and large institutions have $11.5K invested in Amicus Therapeutics in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 292 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 298 → 2 (-296)

100% less funds holding in top 10

Funds holding in top 10: 16 → 0 (-16)

100% less capital invested

Capital invested by funds: $4.81B → $11.5K (-$4.81B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 292

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

105.91% less ownership

Funds ownership: 105.92% → 0% (-106%)

Holders
2
Holders Change
-296
Holders Change %
-99.33%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-16
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
292
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$490M
2
UBS Group
UBS Group
Switzerland
-$231M
3
Vanguard Capital Management
Vanguard Capital Management
Pennsylvania
-$203M
4
PCM
Pentwater Capital Management
Florida
-$202M
5
Vanguard Portfolio Management
Vanguard Portfolio Management
Pennsylvania
-$202M

FOLD Hedge Fund Activity: Q2 2026 in Review

2 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2026, worth a combined $11.5K — down 100% from $4.81B a quarter earlier.

Sellers outnumbered buyers: 292 funds closed out of FOLD and 0 opened new positions — a net loss of 292 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $490M sold.

  • 2 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2026, down from 298 in Q1 2026.
  • Funds reported $11.5K of Amicus Therapeutics stock for Q2 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Amicus Therapeutics positions in Q2 2026 and 292 closed out, a net change of -292 holders.
  • The largest Amicus Therapeutics seller in Q2 2026 was BlackRock, an estimated $490M sold.

Based on aggregated 13F filings for Q2 2026.